Role of liver biopsy in the management of chronic liver disease: Selective rather than routine

Reviews in Gastroenterological Disorders

Volumn 5, Issue 4, 2005, Pages 195-205

  Reiss, Gary ^a   Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis; Human immunodeficiency virus; Liver biopsy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HYALURONIC ACID; INTERFERON; LAMIVUDINE; LOCAL ANESTHETIC AGENT; METFORMIN; PEGINTERFERON; PLACEBO; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG CONTRAINDICATION; DRUG COST; DYSLIPIDEMIA; GENETIC SCREENING; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LABORATORY TEST; LAPAROSCOPY; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER PARENCHYMA; MEDICAL DECISION MAKING; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATIENT SELECTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEROLOGY; SIDE EFFECT; SUPERINFECTION; TISSUE SECTION; VIROLOGY; VIRUS LOAD;

BIOPSY; CHRONIC DISEASE; HUMANS; LIVER DISEASES; PATIENT SELECTION; RISK ASSESSMENT;

EID: 29444448662     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid- 1990s: questions and answers. Semin Liver Dis. 1995;15:340-359.
2. Menghini G. One-second needle biopsy of the liver. Gastroenterology. 1958:35:190-199.
3. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
4. Hultcrantz R, Gabrielsson N. Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionucleotide imaging and liver biopsy. J Intern Med. 1993;233:7-12.
5. Bianchi L. Liver biopsy in elevated liver function tests? An old question revisited. J Hepatol. 2001; 35:195-199.
6. Friedman LS. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep. 2004;6:30-36.
7. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis. 2004;24: 89-97.
8. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39: 275-277.
9. Siddique I, El-Naga HA, Madda JP, et al. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol. 2003;38:427-432.
10. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.
11. Persico M, Palmentieri B, Vecchione R, et al. Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol. 2002;97:491-492.
12. Bejarno PA, Koehler A, Sherman KE. Second opinion pathology in liver biopsy interpretation. Am J Gastroenterol. 2001;96:3158-3164.
13. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology. 2000;32: 477-481.
14. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy: a multicenter retrospective study on 68,276 biopsies. J Hepatol. 1986;2:165-173.
15. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion. 2003:67:138-145.
16. Eisenberg E, Konopniki M, Veitsman E, et al. Prevalence and characteristics of pain induced by percutaneous; biopsy. Anesth Analg. 2003;96: 1392-1396.
17. Garcia G, Keeffe EB. Liver biopsy in chronic hepatitis C: routine or selective. Am J Gastroenterol. 2001;96:3053-3055.
18. Aube C, Oberti F, Korali N, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol. 1999;30:472-478.
19. Phillips MG, Preedy VR, Hughes RD. Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy? Eur J Gastroenterol Hepatol. 2003;15:945-950.
20. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002;36:S57-S64.
21. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.
22. Bissel D. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology. 2004;127:1847-1849.
23. Patel K, Gordon SC, Jacobson I, et al. Performance characteristics of a non-invasive fibrosis marker panel in differentiating minimal stage (F0-F1) from progressively severe fibrosis in chronic hepatitis C patients [abstract]. Gastroenterology. 2003;124:739A.
24. Rosenberg W, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127: 1704-1713.
25. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36:S152-S160.
26. National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 2001;33:196-200.
27. National Institute of Health Consensus Development Conference statement: management of hepatitis C: 2002. June 10-12, 2002. Hepatology. 2002;36(suppl):S3-S20.
28. Yano M, Kumada H, Kage M, et al. The long term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-1340.
29. Bain VG, Bonacini M, Govindarajan S, et al. A multicentre study of the usefulness of liver biopsy in hepatitis C. J Viral Hepat. 2004;11: 375-382.
30. Skelly MM, James PD, Ryder SD. Findings of liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35:195-199.
31. Manns MP, McHutchinson JG, Gordon SC, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965.
32. Andriulli A, Festa V, Leandro G, et al. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection. An AIGO study. Dig Dis Sci. 2001;46:1409-1415.
33. Saadeh S, Cammell G, Carey WD, et al. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33:196-200.
34. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-982.
35. Andriulli A, Persisco M, Iacobellis A, et al. Treatment of patients with HCV infection with or without liver biopsy. J Viral Hepat. 2004;11: 536-542.
36. Wong JB, Bennet WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: risks, benefits and costs. JAMA. 1998;280:2088-2093.
37. Zaman A, Fennerty MB, Keeffe EB. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther. 2003;18:661-670.
38. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol. 1995;90:1250-1257.
39. Pasquale G, Sagnelli E, Coppola N, et al. Uselessness of liver biopsy in patients with hepatitis C virus chronic infection and persistently normal aminotransferase levels. Infez Med. 2003;11:11-17.
40. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histological findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36:973-977.
41. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S161-S172.
42. Alvarez DF, Latorre JS. Hepatitis C virus and HIV coinfection: clinical management and new strategies. AIDS Read. 2004;14:S16-S21.
43. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Inf Dis. 2001; 32:492-497.
44. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1-12.
45. Quereda C, Moreno S, Moreno L, et al. The role of liver biopsy in the management of chronic hepatitis C in patients infected with the human immunodeficiency virus. Hum Pathol. 2004;35: 1083-1087.
46. Merchante N, Macias J, Palacios R, et al. Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus co-infected patients: still a role for liver biopsy? AIDS. 2004;12:1746-1748.
47. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with HCV and HIV. Clin Infec Dis. 2003;36:491-498.
48. Martin -Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency viros-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38: 128-133.
49. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-281.
50. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38:e79-e8O.
51. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
52. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351: 438-450.
53. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.
54. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology. 2001;34:1225-1241.
55. Chang MH, Hwang LY, Hsu HC, et al. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology. 1998;8:374-377.
56. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989;10:761-763.
57. De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39(suppl 1):S3-S25.
58. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. J Gastroenterol Hepatol. 2003;18:239-245.
59. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology. 2004; 39:857-861.
60. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36: 186-194.
61. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87-106.
62. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003;15:539-543.
63. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-723.
64. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123: 745-750.
65. Hübscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2004;16:1107-1115.
66. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
67. Talwalkar JA. Motion-all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol. 2002;16:718-721.
68. Bacon BR, Faravash MJ, Janney CG, et al. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103-1109.
69. Palmer M, Shaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408-1413.
70. Ratziu V, Giral P, Charlotte D, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-1123.
71. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91-100.
72. Sorbi D, McGill DB, Thistle JL, et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities [abstract]. Hepatology. 1999:30:477A.
73. Angulo P. Medical progress: nonalcoholic fatty liver disease. N Engl J Med. 2002;346: 1221-1231.